Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy
24 avr. 2019 06h30 HE
|
Precision Biosciences
DURHAM, N.C., April 24, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome...
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
17 avr. 2019 05h30 HE
|
Precision Biosciences
DURHAM, N.C., April 17, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome...
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
01 avr. 2019 16h05 HE
|
Precision Biosciences
DURHAM, N.C., April 01, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome...
Precision BioSciences Announces Pricing of Initial Public Offering
27 mars 2019 17h50 HE
|
Precision Biosciences
DURHAM, N.C., March 27, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome...